Summary
A phase 2b randomized, double-blind, placebo-controlled study shows that naldemedine, a peripherally acting µ-opioid receptor antagonist, is effective in easing opioid-induced constipation compared to placebo. Phase 3 development is expected for the 0.2 mg/day naldemedine dose.
- naldemedine
- constipation
- opioids
- noncancer pain
- spontaneous bowel movements
- gastroenterology clinical trials
- © 2015 SAGE Publications
Tools
Table of contents
Cited By...
- No citing articles found.